The efforts to develop drugs for neurologic and psychiatric conditions has been plagued with failure. Herophilus is combining organoids derived from patient stem cells along with machine learning to gain new insight into the biology underlying these diseases and discover and develop more effective drugs. We spoke to Saul Kato, co-founder and CEO of Herophilus, about the drug development challenges for these diseases, how his company is using organoids and machine learning to better understand how to target them, and its growing pipeline therapeutic candidates.
